Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment of Newly Diagnosed Patients with High-Risk APL By Ogkologos - September 3, 2025 524 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the APOLLO study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation... July 9, 2025 What People With Cancer Should Know About Immune Checkpoint Inhibitor Side... November 1, 2021 Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases August 26, 2019 The Most Successful Female Singer Of The 1970s Disappeared. Now She’s... May 1, 2019 Load more HOT NEWS ASCO 2021 news: follow-up treatments pave the way FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for... EMA Recommends Granting a Marketing Authorisation for Enfortumab Vedotin for the... FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer
